Diseases: Drugs

Department of Health written question – answered on 8th March 2017.

Alert me about debates like this

Photo of Barry Sheerman Barry Sheerman Labour/Co-operative, Huddersfield

To ask the Secretary of State for Health, if he will publish details of the process leading to the review by NHS England's Clinical Priorities Advisory Group of commissioning of medicines for rare diseases in 2017-18.

Photo of David Mowat David Mowat The Parliamentary Under-Secretary of State for Health

NHS England considers the commissioning of medicines for rare diseases as they would any treatment for any condition. The process for developing clinical policies for treatments is published on the NHS England website:

https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2015/06/nhse-respns-publictn-17-06-15.pdf

In addition, NHS England recently undertook a consultation on the process for prioritising treatments that required investment, and the response to that consultation is published here:

https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2016/06/prioritisation-method-cons-response.pdf

A recent consultation exercise has also been undertaken to consider NHS England’s ‘generic policies’ that consider decision making of treatments outside the annual investment prioritisation process. The outcome of that consultation will be published at a later date once the responses have been fully considered.

Does this answer the above question?

Yes1 person thinks so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.